The role of hormone therapy in the treatment of osteoporosis

References

• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principle results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002; 228(3): 321–33.
   Google Scholar
• Writing Group for the PEPI trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1996; 276:1389–96.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative Randomized Trial. JAMA. 2003; 290(13): 1729–38.
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349(6): 523–34.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Wehren LE, Siris ES, et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause. 2003; 10(5): 412–9.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Hart DM, Clark AC, et al. Bone response to termination of oestrogen treatment. Lancet. 1978; 1; 1325–7.
   PubMed Web of Science ®Google Scholar
• Ascott-Evans BH, Guanabens N, Kivinen S, et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Int Med. 2003; 163(7): 789–94.
   PubMed Web of Science ®Google Scholar
• De Villiers TJ. Individualized therapy for osteoporosis prevention and treatment in women under 60. Climacteric. 2009; 12:210–2.
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee DW, Birkhauser MH, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007; 10:181–94.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297: 1465–77.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ, et al. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. Women's Health (Larchmt). 2006; 15(1): 35–44.
   PubMed Web of Science ®Google Scholar
• Greendale GA, Espeland M, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Int Med. 2002; 162(6): 665–72.
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen MS. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. 1981; 1 (8218)459–61.
   PubMed Web of Science ®Google Scholar
• Bagger Z, Tankó LB, Alexanderson P, et al. Two to three years of hormone replacement treatment in healthy women has long term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone. 2004; 34: 728–35.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280: 605–13.
   Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288(1): 49–57.
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003; 362:428–32.
   PubMed Web of Science ®Google Scholar
• Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005; 112: 3495–500.
   PubMed Web of Science ®Google Scholar
• Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005; 8(1)3–12.
   PubMed Web of Science ®Google Scholar
• Kopper N, Gudemen I, Thompson DJ. Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies. Drug Design Development and Therapy. 2008; 2: 193–202.
   Google Scholar
• Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004(3): 443–51.
   Google Scholar
• Nath A, Sitruk-Ware R. Different cardiovascular effects of progestins according to structure and activity. Climacteric. 2009; 12 Suppl 1: S96–101.
   Google Scholar
• Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. New Engl J Med. 2008; 359(7): 697–708.
   PubMed Web of Science ®Google Scholar